WO2020136232A1 - Protéine m2 à propriété immunosuppressive - Google Patents

Protéine m2 à propriété immunosuppressive Download PDF

Info

Publication number
WO2020136232A1
WO2020136232A1 PCT/EP2019/087059 EP2019087059W WO2020136232A1 WO 2020136232 A1 WO2020136232 A1 WO 2020136232A1 EP 2019087059 W EP2019087059 W EP 2019087059W WO 2020136232 A1 WO2020136232 A1 WO 2020136232A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
composition
residue
poxviral
amino acid
Prior art date
Application number
PCT/EP2019/087059
Other languages
English (en)
Inventor
Patricia KLEINPETER
Jean-Baptiste Marchand
Christelle REMY
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of WO2020136232A1 publication Critical patent/WO2020136232A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptide poxviral (dénommé polypeptide M2) ayant la capacité de se lier aux molécules costimulatrices B7-1 (CD80) et B7-2 (CD86) et de modifier leurs Interactions avec les récepteurs à la surface des lymphocytes T CD28, CTLA4 (pour l'antigène 4 associé aux lymphocytes T cytotoxiques) et/ou PD-L1 (ligand 1 de mort cellulaire programmée). La présente invention concerne également un vecteur d'expression dudit polypeptide M2 poxviral et une composition comprenant ledit polypeptide M2 ou un vecteur d'expression destiné à être utilisé en tant que nouveau médicament immunosuppresseur, ainsi que des procédés de traitement de maladies ou de troubles associés à des réponses immunitaires non adéquates telles que des maladies auto-immunes et des rejets de greffe incluant l'administration d'un tel polypeptide M2, d'un vecteur exprimant M2 ou d'une composition de celui-ci (agent actif). La présente invention concerne en outre des procédés de production d'un tel polypeptide M2.
PCT/EP2019/087059 2018-12-28 2019-12-27 Protéine m2 à propriété immunosuppressive WO2020136232A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18306873 2018-12-28
EP18306873.3 2018-12-28
EP19306023 2019-08-21
EP19306023.3 2019-08-21

Publications (1)

Publication Number Publication Date
WO2020136232A1 true WO2020136232A1 (fr) 2020-07-02

Family

ID=69104445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/087059 WO2020136232A1 (fr) 2018-12-28 2019-12-27 Protéine m2 à propriété immunosuppressive

Country Status (1)

Country Link
WO (1) WO2020136232A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022148736A1 (fr) 2021-01-05 2022-07-14 Transgene Vectorisation de l'anticorps engageant les cellules t muc1

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183070A2 (fr) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation de levures du genre Pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1998010088A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
WO2003053463A2 (fr) 2001-12-10 2003-07-03 Bavarian Nordic A/S Preparations contenant un poxvirus et procede de preparation de compositions stables contenant un poxvirus
US6686152B2 (en) 1999-04-30 2004-02-03 Aclara Biosciences, Inc. Methods employing oligonucleotide-binding e-tag probes
WO2006076003A2 (fr) * 2004-04-16 2006-07-20 Acambis Inc. Souches virales de vaccine
WO2006085082A1 (fr) 2005-02-09 2006-08-17 Stabilitech Ltd. Produit séché
WO2007056847A1 (fr) 2005-11-21 2007-05-24 Sanofi Pasteur Limited Formulations de stabilisation pour virus recombinants
US20070161085A1 (en) 2003-02-25 2007-07-12 Medlmmune Vaccines, Inc. Methods of Producing Influenza Vaccine Compositions
WO2008114021A1 (fr) 2007-03-19 2008-09-25 Stabilitech Ltd. Procédé de conservation de particules virales
WO2008138649A2 (fr) 2007-05-15 2008-11-20 Transgene S.A. Peptides de signalisation
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2009065546A1 (fr) 2007-11-19 2009-05-28 Transgene Sa Vecteurs oncolytiques dérivés de poxvirus
WO2010127115A1 (fr) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Vecteurs d'immunisation modifiés
WO2014053571A1 (fr) 2012-10-02 2014-04-10 Transgene Sa Formulation contenant un virus et utilisation associée

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183070A2 (fr) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation de levures du genre Pichia
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1998010088A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
US6686152B2 (en) 1999-04-30 2004-02-03 Aclara Biosciences, Inc. Methods employing oligonucleotide-binding e-tag probes
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2003053463A2 (fr) 2001-12-10 2003-07-03 Bavarian Nordic A/S Preparations contenant un poxvirus et procede de preparation de compositions stables contenant un poxvirus
US20070161085A1 (en) 2003-02-25 2007-07-12 Medlmmune Vaccines, Inc. Methods of Producing Influenza Vaccine Compositions
WO2006076003A2 (fr) * 2004-04-16 2006-07-20 Acambis Inc. Souches virales de vaccine
WO2006085082A1 (fr) 2005-02-09 2006-08-17 Stabilitech Ltd. Produit séché
WO2007056847A1 (fr) 2005-11-21 2007-05-24 Sanofi Pasteur Limited Formulations de stabilisation pour virus recombinants
WO2008114021A1 (fr) 2007-03-19 2008-09-25 Stabilitech Ltd. Procédé de conservation de particules virales
WO2008138649A2 (fr) 2007-05-15 2008-11-20 Transgene S.A. Peptides de signalisation
WO2009065546A1 (fr) 2007-11-19 2009-05-28 Transgene Sa Vecteurs oncolytiques dérivés de poxvirus
WO2010127115A1 (fr) * 2009-04-30 2010-11-04 Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) Vecteurs d'immunisation modifiés
WO2014053571A1 (fr) 2012-10-02 2014-04-10 Transgene Sa Formulation contenant un virus et utilisation associée

Non-Patent Citations (71)

* Cited by examiner, † Cited by third party
Title
"Fundamental Immunology", 1989, RAVEN PRESS, pages: 846 - 856
"GenBank", Database accession no. AST09586.1
"Genbank", Database accession no. YP_009281778.1
"Methods in Enzymology", vol. 182, 1990, SPRINGER- VERLAG, article "Protein Purification: Principles and Practice"
"Uniprot", Database accession no. P21092
A. GENNARO: "Edition of Remington: The Science and Practice of Pharmacy", LIPPINCOTT, WILLIAMS&WILKINS
ALFONSO ET AL., J. VIROL., vol. 86, no. 9, 2012, pages 5039 - 54
AMANN ET AL., GENE, vol. 69, 1988, pages 301 - 15
ANTOINE ET AL., VIROLOGY, vol. 244, no. 2, 1998, pages 365 - 96
BAOMING LIU ET AL., J. VIROL., vol. 92, no. 7, 2018, pages e02152 - 17
BOILING ET AL., TRANSPLANT, vol. 453, 1992, pages 283 - 6
BUTTE ET AL., IMMUNITY, vol. 27, 2007, pages 111 - 122
CHAKRABARTI ET AL., BIOTECHNIQUES, vol. 23, 1997, pages 1094 - 7
CHANG ET AL., NATURE, vol. 198, 1977, pages 1056
CHAPMAN ET AL., ADV. DRUG DELIV. REV., vol. 54, no. 4, 2002, pages 531 - 45
CHAPOVAL ET AL., METHODS MOL MED., vol. 45, 2000, pages 247 - 55
CHARTIER ET AL., J. VIROL., vol. 70, 1996, pages 4805 - 10
CHEN, NAT. REV. IMMUNOL., vol. 4, 2004, pages 336 - 347
COLBERRE-GARAPIN ET AL., J. MOL. BIOL., vol. 150, 1981, pages 1
DENIS ET AL., J. BIOL. CHEM., vol. 25, 1983, pages 1165
EMAMAULLEE, EXPERT OPIN. BIOL THER., vol. 9, no. 6, 2009, pages 789 - 96
ERBS ET AL., CANCER GENE THER., vol. 15, no. 1, 2008, pages 18 - 28
EVANS ET AL., J PHARM SCI., vol. 93, 2004, pages 2458 - 75
FALLAUX ET AL., HUM GENE THER., vol. 9, 1998, pages 1909 - 17
FLEISCHAUER ET AL., J. GENERAL VIROLOGY, vol. 96, no. 9, 2015
GANDHI ET AL., CURR OPIN ORGAN TRANSPLANT, vol. 13, 2008, pages 622 - 6
GEDEY ET AL., J. VIROL., vol. 80, 2006, pages 8676 - 85
GOEDDEL ET AL., NUCLEIC ACIDS RES., vol. 8, 1980, pages 4057
GOSSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 5547 - 51
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 - 74
GUARENTE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 2199 - 9
HAMMOND ET AL., J. VIROL METHODS, vol. 66, 1997, pages 135 - 8
HEALY ET AL., EUR J CARDIOTHORAC SURG, vol. 29, 2006, pages 760 - 6
HESS ET AL., J. ADV. ENZYME REG., vol. 7, 1968, pages 149
HIMOUDI ET AL., J. VIROL., vol. 76, 2002, pages 12735 - 46
HINTHONG ET AL., VIROLOGY, vol. 373, no. 2, 2008, pages 248 - 262
HOLLAND ET AL., BIOCHEMISTRY, vol. 17, 1978, pages 4900
HU ET AL., J. VIROL., vol. 75, no. 8, 2001, pages 10300 - 8
HUANGMCDONALD, BIOCHEMICAL ENGINEERING JOURNAL, vol. 45, no. 3, 2009, pages 168 - 84
INOKUCHI ET AL., MOL. CELL. BIOL., vol. 7, 1987, pages 3185 - 93
INOUYE ET AL., NUCLEIC ACIDS RES., vol. 13, 1985, pages 3101 - 9
KAUFMAN ET AL., EMBO J., vol. 6, 1987, pages 187 - 95
KHIEW ET AL., JCI INSIGHT, vol. 2, no. 9, 2017, pages 92033
KIM ET AL., J. VIROL., vol. 69, 1995, pages 2565 - 73
KUJAN ET AL., CELL, vol. 30, 1982, pages 933 - 43
KUMARBOYLE, VIROLOGY, vol. 179, 1990, pages 151 - 8
LENSCHOW ET AL., SCIENCE, vol. 257, 1992, pages 789 - 92
MAGARI ET AL., J. CLIN. INVEST., vol. 100, 1997, pages 2865 - 72
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 51
MC IVOR ET AL., MOL. CELL BIOL., vol. 7, 1987, pages 838 - 48
METHODS IN ENZYMOLOGY, 1990, pages 182
NEEDLEMANWUNSH, J.MOL. BIOL., vol. 48, 1970, pages 443 - 453
NO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 3346 - 51
PAUL ET AL., CANCER GENE THER., vol. 9, 2002, pages 470 - 7
PILLAI ET AL., WORLD J GASTROENTEROL, vol. 15, no. 34, 2009, pages 4225 - 33
R. GEDEY ET AL: "Poxviral Regulation of the Host NF- B Response: the Vaccinia Virus M2L Protein Inhibits Induction of NF- B Activation via an ERK2 Pathway in Virus-Infected Human Embryonic Kidney Cells", JOURNAL OF VIROLOGY., vol. 80, no. 17, 1 September 2006 (2006-09-01), US, pages 8676 - 8685, XP055676204, ISSN: 0022-538X, DOI: 10.1128/JVI.00935-06 *
SAMBROOK ET AL.: "Molecular Cloning-A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY
SANTERRE ET AL., GENE, vol. 30, 1984, pages 147
SCHULTZ ET AL., GENE, vol. 60, 1987, pages 113 - 201
SEED, NATURE, vol. 329, 1987, pages 840
SHIMATAKE ET AL., NATURE, vol. 292, 1981, pages 128
SMITH, VACCINE, vol. 11, 1993, pages 43 - 53
SMITHKOTWAL, CRIT. REV. MICROBIOL., vol. 28, no. 3, 2002, pages 149 - 85
SMITHSON ET AL., VIRUS GENES, vol. 53, no. 6, 2017, pages 883 - 97
STUDIER ET AL., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY, vol. 185, 1990, pages 60 - 89
TAN ET AL., BLOOD, vol. 106, no. 9, 2005, pages 2936 - 43
TURKA ET AL., PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 11102 - 5
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
VAN HEEKE ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5503 - 9
VINCENTI ET AL., J ALLERGY CLIN IMMUNOL, vol. 121, no. 2, 2014, pages 299 - 306
WANG ET AL., NAT. BIOTECH., vol. 15, 1997, pages 239 - 43

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022148736A1 (fr) 2021-01-05 2022-07-14 Transgene Vectorisation de l'anticorps engageant les cellules t muc1

Similar Documents

Publication Publication Date Title
AU2018201071B2 (en) Therapeutic nuclease compositions and methods
RU2659423C2 (ru) ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
EP3202415B1 (fr) Rotéine de fusion comprenant la c1orf32 et un ou plusieurs domaines de la région constante de la chaine constante d'immunuoglobuline pour le traitement de la sclérose en plaques, la polyarthrite rhumatoïde et d'autres maladies auto-immunes
CN105378075B (zh) 组氨酰-trna合成酶-fc缀合物
EP2403864B1 (fr) Motifs structuraux de polypeptides associés à une activité de signalisation cellulaire
US20220315641A9 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US20210052727A1 (en) Cytokine fusion proteins
JP2013503205A (ja) 移植拒絶反応を阻害するための方法および組成物
DK2776460T3 (en) Fusion protein comprising interleukin 4 and interleukin 10
EP3185885B1 (fr) Polypeptides et leurs utilisations en tant que médicament pour le traitement de troubles auto-immuns
KR20170084033A (ko) 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2020113403A1 (fr) Protéines de fusion de cytokines
Lorenzo et al. APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis
US20210032346A1 (en) B7-h4 antibodies and methods of use thereof
WO2020136232A1 (fr) Protéine m2 à propriété immunosuppressive
JP2012520081A (ja) Ｓｐａｒｃ血管新生ドメイン及び使用方法
CN110623977A (zh) 靶向bcma的嵌合抗原受体t细胞在自身免疫性疾病中的应用
WO2018071528A1 (fr) Protéines et méthode de traitement de l'obésité et de comorbidités associées
US11174322B2 (en) Antibodies and peptides to treat HCMV related diseases
TWI835773B (zh) 組合物及使用方法
AU2021205639A1 (en) Rspo1 proteins and their use
WO2022218997A1 (fr) Nouveau système de présentation de vaccin universel
CN110628722A (zh) 靶向cd20的嵌合抗原受体t细胞在自身免疫性疾病中的应用
CN110623979A (zh) 靶向cd19的嵌合抗原受体t细胞在自身免疫性疾病中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19831761

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19831761

Country of ref document: EP

Kind code of ref document: A1